E!11808 Portable point-of-care test portfolio for instant veterinarian diagnostics

The overall goal is to deliver a portfolio of cost-effective point-of-care tests for the veterinarian market. The tests are to be analysed instantly on a portable platform with the performance of current laboratory-based analysis. The first line of products developed was against two major acute phase proteins (APPs); C-reactive protein (CRP) for dog and serum amyloid A (SAA) for horse. APPs assist the innate immune systems acute phase response (APR) in defending the host against pathological damage, promote healing and restoring homeostasis upon various deteriorating stimuli such as infection, inflammation, trauma, stress, and neoplasia. The rapid response upon stimuli and short half-life makes APPs ideal markers of health in both humans and animals, providing a snapshot of current health status of the patient. The second line of products to be developed is aimed to pinpoint Hemoglobin in canine salvia, Fasciola, Giardia, and canine Calprotectin. Together, the first line and second line products will provide the veterinarian with rapid diagnostics tools that will benefit animal welfare. The tests will be cost-effective for the veterinarians and the owners.

Prosjektet vil resultere i et nyttig verktøy for veterinærer for en enkel, rask og robust måte utføre analyse av pasienter både på klinikk, på hjemmebesøk og ute i felt. Økt test av akkuttfaseproteiner vil bidra til å redusere bruk av antibiotika der dette ikke er strengt nødvendig.

The overall goal is to deliver the veterinarian market with a portfolio of instant quantitative diagnostics test with the performance of current laboratory-based analysers on a cost effective point-of-care platform. The first line of products to be developed is against major acute phase proteins (APPs), such as C-reactive protein (CRP) and serum amyloid A (SAA). APPs assist the innate immune systems acute phase response (APR) in defending the host against pathological damage, promote healing and restoring homeostasis upon various deteriorating stimuli such as infection, inflammation, trauma, stress, and neoplasia. The rapid response upon stimuli and short half-life make APPs ideal markers of health in both humans and animals providing a snapshot of current health status of the object. The second line of products to be developed is aimed to pinpoint organ systems that are affected after confirming or denouncing a progressing acute phase response. These tests will target known biomarkers that is aberrantly expressed upon onset of organ specific diseases. Together, the first line and second line products will provide the veterinarian with rapid diagnostics tools that will benefit animal welfare. The tests will be cost-effective for the veterinarians and the owners. We would primarily develop the second line of tests for the canine breeds. However the targeted biomarkers are in many cases conserved among animal species allowing heterologous (multispecies) detection.